Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion evidence source_evidence_literature NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion SIO_000772 25524798 NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion wasDerivedFrom befree-2016 NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion wasGeneratedBy ECO_0000203 NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- befree-2016 importedOn "2016-02-19" NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.